A $100 million ad blitz has whipped up patient demand for Harvoni, the
$1,100-a-pill hepatitis C treatment, even as the drug's price has drawn a
barrage of lawsuits, state investigations, and sharp condemnation from
members of Congress.
--
Harvoni, made by Gilead Sciences of Foster City, California.
--
Just a handful of prescription drugs were advertised more widely, and
most of those treat conditions — such as erectile dysfunction and
psoriasis — that afflict far more patients in the United States than
hepatitis C. About 3.5 million Americans have the viral infection, which usually lies dormant for years but can eventually cause liver failure and liver cancer.
--
Before discounts, a full course of Harvoni is priced at $94,500.
--
Amid all this negative publicity, U.S. sales of Harvoni slowed down in
the fourth quarter of last year — but the drug remains a blockbuster.
It's generated $12 billion in U.S. sales since its approval in late
2014.
http://theweek.com/articles/611978/inside-100-million-ad-blitz-1100apill-drug-hepatitis-c
Inga kommentarer:
Skicka en kommentar